Theo A.M. van Os

3.6k citations

19 papers · 988 indexed · h-index 15

Co-authors: Margreet G.E.M. Ausems Hans F. A. Vasen Anja Wagner Hanne Meijers‐Heijboer E. Gómez Senno Verhoef Evelien Dekker Rolf H. Sijmons
Topics: Genetic factors in colorectal cancer (6 papers)BRCA gene mutations in cancer (4 papers)Epigenetics and DNA Methylation (4 papers)
Cited by: Pathology and Forensic Medicine Oncology Cancer Research
Journals: Journal of Clinical Oncology JNCI Journal of the National Cancer Institute Gut
Partner nations: Netherlands Germany United States

In The Last Decade

Theo A.M. van Os

19 papers receiving 967 citations

Peers

Countries citing papers authored by Theo A.M. van Os

Since Specialization

Citations

This map shows the geographic impact of Theo A.M. van Os's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Theo A.M. van Os with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Theo A.M. van Os more than expected).

Fields of papers citing papers by Theo A.M. van Os

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Theo A.M. van Os. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Theo A.M. van Os. The network helps show where Theo A.M. van Os may publish in the future.

Co-authorship network of co-authors of Theo A.M. van Os

This figure shows the co-authorship network connecting the top 25 collaborators of Theo A.M. van Os. A scholar is included among the top collaborators of Theo A.M. van Os based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Theo A.M. van Os. Theo A.M. van Os is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers 2018 ·British Journal of Cancer ·(unknown),I. A. P. Derks-Smeets,(unknown),Christine de Die‐Smulders,Vivianne C. G. Tjan‐Heijnen,Ron J T van Golde,Luc Smits,(unknown),Christi J. van Asperen,Margreet G.E.M. Ausems,Margriet Collée,Klaartje van Engelen,C. Marleen Kets,Lizet van der Kolk,Jan C. Oosterwijk,Theo A.M. van Os,Matti A. Rookus,Flora E. van Leeuwen,E. Gómez	17
2	Performance of BRCA1/2 mutation prediction models in male breast cancer patients 2017 ·Clinical Genetics ·Setareh Moghadasi,(unknown),Luc Janssen,(unknown),Mar Rodríguez‐Girondo,Wendy A.G. van Zelst–Stams,Jan C. Oosterwijk,Margreet G.E.M. Ausems,Reinhard Oldenburg,Muriel A. Adank,Eveline W Blom,Mariëlle Ruijs,Theo A.M. van Os,Carolien H. M. van Deurzen,(unknown),(unknown),Juul Wijnen,Maaike P.G. Vreeswijk,Christi J. van Asperen	3
3	A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation? 2016 ·BMC Cancer ·(unknown),(unknown),Barbara A.J. Bastiaansen,Theo A.M. van Os,F.E. van Leeuwen,Monique E. van Leerdam,Evelien Dekker	3
4	Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction 2015 ·JNCI Journal of the National Cancer Institute ·B.A.M. Heemskerk-Gerritsen,Caroline Seynaeve,C. J. van Asperen,Margreet G.E.M. Ausems,J.M. Collée,Helena C. van Doorn,E. Gómez,C. Marleen Kets,Flora E. van Leeuwen,Hanne Meijers‐Heijboer,Marian J.E. Mourits,Theo A.M. van Os,Hans F. A. Vasen,Senno Verhoef,Matti A. Rookus,Maartje J. Hooning	133
5	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Janet R. Vos,(unknown),Dorina M. van der Kolk,Marian J.E. Mourits,Matti A. Rookus,Flora E. van Leeuwen,Margriet Collée,Christi J. van Asperen,Arjen R. Mensenkamp,Margreet G.E.M. Ausems,Theo A.M. van Os,Hanne Meijers‐Heijboer,E. Gómez,Hans F. A. Vasen,Richard M. Brohet,Annemarie H. van der Hout,Liesbeth Jansen,Jan C. Oosterwijk,Geertruida H. de Bock	8
6	Yield of Screening Colonoscopy in First-degree Relatives of Patients With Serrated Polyposis Syndrome 2014 ·Journal of Clinical Gastroenterology ·Yark Hazewinkel,(unknown),Karam S. Boparai,Theo A.M. van Os,Kristien M.A.J. Tytgat,Susanne van Eeden,Paul Fockens,Evelien Dekker	15
7	Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives 2013 ·Familial Cancer ·Yark Hazewinkel,Johannes B. Reitsma,Fokko M. Nagengast,Hans F. A. Vasen,Theo A.M. van Os,Monique E. van Leerdam,(unknown),Evelien Dekker	20
8	Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation 2013 ·Journal of Clinical Oncology ·(unknown),Ward H. van der Ven,Theo A.M. van Os,Peter W.A. Kunst,(unknown),Roy J. Reinten,Rama Krishna Kancha,Justus Duyster,Carel J.M. van Noesel	47
9	Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas 2012 ·Journal of Medical Genetics ·Femme Harinck,Irma Kluijt,Nienke van der Stoep,Rogier A. Oldenburg,Anja Wagner,Cora M. Aalfs,Rolf H. Sijmons,Jan‐Werner Poley,Ernst J. Kuipers,Paul Fockens,Theo A.M. van Os,Marco J. Bruno	29
10	CDH1‐related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling 2011 ·International Journal of Cancer ·Irma Kluijt,Ester Siemerink,Margreet G.E.M. Ausems,Theo A.M. van Os,Daphne de Jong,Joana Simões‐Correia,J. Han van Krieken,Marjolijn J. L. Ligtenberg,Joana Figueiredo,E. van Riel,Rolf H. Sijmons,John Theodorus Plukker,Richard van Hillegersberg,Evelien Dekker,Carla Oliveíra,Annemieke Cats,Nicoline Hoogerbrugge,(unknown)	90
11	Compliance with periodic surveillance for Von-Hippel-Lindau disease 2011 ·Genetics in Medicine ·(unknown),Neil K. Aaronson,Frederik J. Hes,Thera P. Links,Bernard A. Zonnenberg,Jacques W.M. Lenders,Daniëlle Majoor‐Krakauer,Theo A.M. van Os,E. Gómez,Wouter W. de Herder,Rob B. van der Luijt,Ans M.W. van den Ouweland,(unknown),Senno Verhoef,Eveline M. A. Bleiker	12
12	Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes 2011 ·Psycho-Oncology ·(unknown),Eveline M. A. Bleiker,Senno Verhoef,Margreet G.E.M. Ausems,Daniëlle Majoor‐Krakauer,Rolf H. Sijmons,Frederik J. Hes,E. Gómez,Theo A.M. van Os,Liesbeth Spruijt,Rob B. van der Luijt,A.M.W. van den Ouweland,Mariëlle Ruijs,Chad M. Gundy,(unknown),Neil K. Aaronson	24
13	Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas 2010 ·Journal of Medical Genetics ·Imke Christiaans,(unknown),(unknown),Theo A.M. van Os,Frank Baas,Pepijn van den Munckhof,Alexa Kidd,Theo J.M. Hulsebos	105
14	Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome 2010 ·Gut ·(unknown),Johannes B. Reitsma,V. Lemmens,Theo A.M. van Os,E. M. H. Mathus-Vliegen,Jan J. Koornstra,Fokko M. Nagengast,Liselotte P. van Hest,Josbert J. Keller,Evelien Dekker	88
15	Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefits 2010 ·Familial Cancer ·(unknown),Eveline M. A. Bleiker,Neil K. Aaronson,Anja Wagner,Rolf H. Sijmons,Margreet G.E.M. Ausems,A. H. J. T. Vriends,Mariëlle Ruijs,Theo A.M. van Os,Liesbeth Spruijt,E. Gómez,Annemieke Cats,(unknown),Senno Verhoef	53
16	Genetic Testing in Li-Fraumeni Syndrome: Uptake and Psychosocial Consequences 2010 ·Journal of Clinical Oncology ·(unknown),Neil K. Aaronson,Anja Wagner,Rolf H. Sijmons,Margreet G.E.M. Ausems,A. H. J. T. Vriends,Mariëlle Ruijs,Theo A.M. van Os,Liesbeth Spruijt,E. Gómez,Irma Kluijt,(unknown),Senno Verhoef,Eveline M. A. Bleiker	75
17	Birt-Hogg-Dubé Syndrome: Clinical and Genetic Studies of 20 Families 2007 ·Journal of Investigative Dermatology ·Edward M. Leter,(unknown),Gilles Thomas,Theo A.M. van Os,(unknown),Eric F. David,Elisabeth H. Jaspars,Pieter E. Postmus,R. Jeroen A. van Moorselaar,Mikael E. Craanen,Theo M. Starink,Fred H. Menko	59
18	Microsatellite Instability, Immunohistochemistry, and Additional PMS2 Staining in Suspected Hereditary Nonpolyposis Colorectal Cancer 2004 ·Clinical Cancer Research ·Andrea E. van der Meulen‐de Jong,Marjo van Puijenbroek,Yvonne Hendriks,Carli Tops,Juul Wijnen,Margreet G.E.M. Ausems,Hanne Meijers‐Heijboer,Anja Wagner,Theo A.M. van Os,Annette Bröcker‐Vriends,Hans F. A. Vasen,Hans Morreau	173
19	Explorative Study of Costs, Effects and Savings of Screening for Female Fragile X Premutation and Full Mutation Carriers in the General Population 1998 ·Public Health Genomics ·(unknown),Theo A.M. van Os,Johan Polder,Leo P. ten Kate,(unknown)	34

About Theo A.M. van Os

Theo A.M. van Os is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics, having authored 19 papers that have together received 988 indexed citations. Recurring topics across this work include Genetic factors in colorectal cancer (6 papers), BRCA gene mutations in cancer (4 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (409 citations), Oncology (433 citations) and Cancer Research (236 citations). Theo A.M. van Os has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Margreet G.E.M. Ausems, Hans F. A. Vasen, Anja Wagner, Hanne Meijers‐Heijboer, E. Gómez, Senno Verhoef, Evelien Dekker, Rolf H. Sijmons, Juul Wijnen and Carli Tops. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Gut.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact